XLIFE-SCIENCES-AG
8.1.2021 09:10:26 CET | Business Wire | Press release
Xlife Sciences AG has reached a licensing agreement with the biotech firm Baliopharm AG, located in Basel. According to the agreement, Xlife Sciences AG will receive 10% of future income from license fees of Baliopharm AG. The Basel-based company is a leader in innovative antibody therapies for the treatment of acute and chronic inflammatory diseases.
According to the concluded licensing agreement with Baliopharm AG, Xlife Sciences AG will receive 10% of all future licensing income up to a maximum of 300 million euros. This applies to the company's entire line of active ingredients. Xlife Sciences AG thus participates directly in the future success and innovative strength of a leading biotech company in the field of antibody therapies with this transaction.
On the 18th of December, Baliopharm AG received the approval to start Phase I of medical drug Atrosimab for the treatment of Non-Alcoholic SteatoHepatitis (NASH) by the Australian Healthcare Administration. NASH is the most frequent chronic liver disease. The Global Liver Institute estimates that there are more than 115 million people affected globally by NASH. According to the Institute, this number could double by 2030. In Germany, 1.5 to 2 million patients have at least a mild form of NASH. Under more severe circumstances, the disease can lead to irreversible liver damage (liver cirrhosis) and cannot be treated therapeutically. In this way, Baliopharm AG views this as a huge market.
About Xlife Sciences AG
Xlife Sciences AG is a Swiss company with focus on investing in promising technologies in the life science industry. Xlife Sciences AG is building the bridge from research and development to healthcare markets by supporting researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. Together with industrial partners or universities, Xlife Sciences AG leads projects through the proof-of-concept phase after an invention disclosure or start-up. Subsequently, the firm focuses on out-licensing or selling the company, often with a combination of a strategic partnership. Xlife Sciences AG offers its investors direct access to the further development of innovative and future-oriented technologies at a very early stage. For more information, please visit: www.xlifesciences.ch
Language: |
English |
Company: |
Xlife Sciences AG |
Klausstrasse 19 |
|
8008 Zürich |
|
Switzerland |
|
Phone: |
0041 44 385 84 60 |
E-mail: |
|
Internet: |
|
ISIN: |
CH0461929603 |
WKN: |
A2PK6Z |
Listed: |
Regulated Unofficial Market in Frankfurt, Munich |
EQS News ID: |
1159182 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20210108005126/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The LYCRA Company Makes NSC Safety Congress & Expo Debut10.9.2026 19:45:00 CEST | Press release
Highlights Innovative Fibers That Enhance Worker Comfort, Performance, and Protection The LYCRA Company, a global leader in developing fiber and technology solutions for the apparel and personal care industries, today announced its inaugural exhibition at the NSC Safety Congress & Expo, being held September 14-16 in Indianapolis. The company also marks the North American debut of its “FIBERS THATWORK” portfolio of innovative solutions for workwear, uniforms, and protective apparel. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260910402207/en/ The LYCRA Company will debut its FIBERS THAT WORK portfolio at the NSC Safety Congress & Expo in Indianapolis, highlighting fiber technologies engineered to enhance comfort, durability, visibility, and protection in workwear and protective apparel. "Comfort is fundamental to workwear performance," said Tara Maurer-Mackay, product category director, branded specialty products at The LY
Turning Up the Heat: ProAmpac Helps Power Circle K’s Flamin’ Hot® Boneless Chicken Wings Launch10.9.2026 18:12:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, is proud to announce its role in supporting Circle K's launch of Flamin' Hot® Boneless Chicken Wings, created in partnership with PepsiCo/Frito-Lay. Designed to address key challenges in hot food packaging, ProAmpac's custom fiber-based tray helps maintain food quality, improve shelf appeal, and enhance the consumer experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260910495607/en/ Flamin' Hot Chicken Bites Circle K sought a better way to merchandise its Flamin’ Hot® Boneless Chicken Wings while addressing several performance challenges, including heat retention, moisture loss, and grease resistance, while extending hot hold time. ProAmpac responded with a custom tray designed specifically for the recipe and portion size, demonstrating its flexibility in meeting unique customer design and performance requirements. Working from PepsiCo’s initial br
Record Currency Management wins new FX Alpha and Frontier Market mandates10.9.2026 17:30:00 CEST | Press release
Record Currency Management Ltd (RCM), a subsidiary of London-listed Record plc (Record Financial Group), is pleased to announce that it has been awarded two new mandates of strategic importance – an FX Alpha mandate and an FX Frontier mandate. RCM is the UK currency management arm of Record Financial Group, the London-listed specialist investment group managing over USD 122 billion of assets on behalf of institutional clients worldwide. Record’s client base comprises pension funds, foundations, sovereign institutions and other asset managers, with whom the Group has built long-standing relationships through its focus on bespoke investment and risk management solutions. Headquartered in London, Record has offices in Hamburg, Zurich, Zug, New York, and Hong Kong. For institutional investors, currency can represent both a source of risk and a potential source of differentiated returns. Live since 2012, Record’s FX Alpha strategy aims to deliver attractive risk-adjusted returns without cap
Azizi Developments Introduces USD 8.1 Billion Master-Planned Community Azizi Florence in Sharjah10.9.2026 16:08:00 CEST | Press release
Azizi Developments, a leading private developer in the UAE, is unveiling Azizi Florence, a USD 8.1 billion master-planned community marking its first project in Sharjah. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260910091949/en/ Azizi Florence (Photo: AETOSWire) The freehold development will feature 1,130 villas, more than 6,000 townhouses and 3,500 apartments, with three-bedroom townhouses starting from USD 515,000 at USD 231 per square foot of sellable area. Designed as an integrated destination, Azizi Florence will bring together residential, retail, hospitality, education, leisure and wellness offerings, centred around a 1.7-million-square-foot Central Park. Six residential clusters will each feature a park, clubhouse, community centre and landscaped gardens. Mr. Mirwais Azizi, Founder and Chairman of Azizi Group, said: “Returning to Sharjah after more than three decades is deeply meaningful to me, as this emirate w
Agentic Crypto Payments Have Surged by 500%1 in the Last Three Months, Crypto Compliance Must Become Agentic Too10.9.2026 15:53:00 CEST | Press release
Elliptic is publishing eight principles for governing agentic on-chain risk: the Elliptic Standard Elliptic,the global leader in on-chain risk, today published the Elliptic Standard: eight principles for governing agentic on-chain risk. Elliptic has been at the intersection of financial crime and on-chain finance since 2013, long enough to recognize the shift to agentic transactions as a defining inflection point in financial crime risk, and to be the first to define what governing it demands. On-chain finance is now running at agentic speed. Machines are originating, authorizing and settling transactions at a volume no human team can review. Illicit actors are using AI to evade detection at a speed and volume that manual processes cannot track. Models built around human review were never designed for this world. They are already overwhelmed. Three forces are driving this shift. First, autonomous agents are increasingly the counterparty on both sides of a transaction, not just people i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom